Gambogic Acid / P53 Cancer Research Results

GamB, Gambogic Acid: Click to Expand ⟱
Features:
Gambogic acid is a naturally occurring xanthonoid extracted from the resin of trees belonging to the Garcinia genus—most notably, Garcinia hanburyi. This tree is native to regions in Southeast Asia, particularly found in areas of China, India, and neighboring countries.
Gambogic acid (GA; C38H44O8, MW: 628.76), a polyprenylated xanthone and a widely used coloring agent, is the main active ingredient of gamboges secreted from the Garcinia hanburyi tree ([3, 4], which mainly grows in Southeast Asia.
GA has been approved by the Chinese FDA for the treatment of solid cancers in Phase II clinical trials.

Pathways:
-evidence suggesting that it can inhibit thioredoxin reductase (TrxR).
-can indeed lead to an increase in reactive oxygen species (ROS) levels
-Gambogic acid can trigger mitochondrial dysfunction, leading to cytochrome c release
-influences death receptors
-Inhibition of NF-κB Signaling
-Inhibition of VEGF Pathway
-Cell Cycle Arrest:
-p53 Activation

Gambogic acid — a naturally occurring, highly prenylated caged xanthone isolated principally from gamboge resin produced by Garcinia hanburyi. It is an experimental small-molecule anticancer agent commonly abbreviated GA or GBA, with the molecular formula C38H44O8. GA is an electrophilic, multi-target compound whose α,β-unsaturated carbonyl groups can covalently modify reactive cysteine residues in redox-regulatory and proteostasis proteins. It has undergone limited Phase I and Phase IIa clinical investigation in China as an intravenous formulation but is not an established or broadly approved anticancer drug.

Primary mechanisms (ranked):

  1. Covalent inhibition of thioredoxin and thioredoxin reductase, with additional inhibition of PRDX1 and related thiol-dependent antioxidant systems, causing collapse of tumor-cell redox buffering.
  2. ROS accumulation followed by mitochondrial membrane depolarization, cytochrome-c release, Bax/Bcl-2 imbalance, caspase activation, apoptosis, and in some models GSDME-dependent pyroptosis.
  3. Covalent inhibition of 6-phosphogluconate dehydrogenase, suppressing the oxidative pentose phosphate pathway, NADPH generation, and antioxidant regeneration.
  4. Disruption of thiol proteostasis, proteasome function, HSP90-dependent client-protein stability, and endoplasmic-reticulum homeostasis, producing ER stress, unfolded-protein responses, autophagy, paraptosis, or apoptosis.
  5. Suppression of PI3K–AKT–mTOR, NF-κB, STAT3, survivin, and other pro-survival signaling pathways.
  6. Cell-cycle arrest through context-dependent activation of p53 and p21 and suppression of cyclin D1 and related proliferative regulators.
  7. Inhibition of angiogenesis, invasion, and metastasis through reduced HIF-1α, VEGF, MMP-2, MMP-9, and epithelial–mesenchymal transition signaling.
  8. Chemosensitization and reversal of multidrug resistance through inhibition of P-glycoprotein, survivin, NF-κB, and stress-adaptation pathways; radiosensitization has also been reported preclinically.

Bioavailability / PK relevance: GA is highly lipophilic, poorly water-soluble, chemically reactive, and rapidly distributed and metabolized. Human studies have used intravenous GA formulations rather than conventional oral dosing. A major circulating human metabolite is 10-hydroxygambogic acid. Short systemic persistence, formulation-dependent exposure, local irritation, and limited aqueous solubility have driven extensive investigation of liposomes, albumin carriers, polymeric nanoparticles, solid-lipid nanoparticles, and other targeted delivery systems. Preclinical toxicology identifies the liver and kidney as principal dose-limiting target organs, with potential drug-interaction concerns related to CYP3A4 and transporter modulation.

In-vitro vs systemic exposure relevance: Many mechanistic studies use approximately micromolar GA concentrations and short, direct cellular exposure. These conditions may produce greater free-drug exposure than is safely sustained in plasma or tissues because GA is poorly soluble, extensively protein-bound, rapidly metabolized, and systemically toxic at higher exposure. Covalent target engagement may permit biological activity despite transient exposure, but concentration-dependent cell-culture findings should not be assumed to translate directly to achievable unencapsulated systemic dosing.

Clinical evidence status: Predominantly preclinical, with limited small-human evidence. An open-label, randomized, multicentre Phase IIa study evaluated different intravenous dosing schedules in patients with advanced solid malignancies and reported mainly grade 1–2 adverse effects, but the study was small, lacked a placebo or standard-treatment control, and did not establish definitive efficacy. There is no robust confirmatory randomized trial evidence, no established survival benefit, and no routine clinical role. GA should therefore be classified as an investigational natural-product-derived anticancer agent rather than an approved chemotherapy.

Gambogic Acid Mechanistic Ranking

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Thioredoxin and thioredoxin reductase inhibition ↓ Trx1, Trx2 and TrxR activity ↓ antioxidant capacity possible P Redox-buffering collapse Core electrophilic mechanism involving covalent modification of catalytic or regulatory cysteine residues.
2 Peroxiredoxin and thiol proteostasis ↓ PRDX1 function; ↓ thiol proteostasis Potential oxidative and proteotoxic injury P–R Loss of peroxide detoxification and protein homeostasis PRDX1 has been identified as a direct covalent target; target relevance may vary by tumor type.
3 Reactive oxygen species accumulation ↑ ROS ↑ ROS at sufficient exposure P–R Oxidative-stress overload Central downstream consequence of antioxidant-system inhibition; not inherently cancer-selective.
4 Pentose phosphate pathway and 6PGD ↓ 6PGD; ↓ PPP; ↓ NADPH ↓ NADPH possible R Metabolic and antioxidant restriction GA covalently inhibits 6PGD, limiting NADPH production and reinforcing oxidative stress.
5 Mitochondrial membrane integrity ↓ membrane potential; ↑ cytochrome c release Mitochondrial toxicity possible R Intrinsic apoptosis initiation Frequently linked to ROS, p53, Bax activation, and Bcl-2 suppression.
6 Apoptosis and pyroptosis execution ↑ caspase-3, caspase-8 and caspase-9; ↑ GSDME cleavage Cell death possible at toxic exposure R–G Programmed cell death Predominantly apoptosis; GSDME-dependent pyroptosis occurs in selected GSDME-expressing models.
7 Endoplasmic reticulum stress and unfolded-protein response ↑ PERK, ATF6, GRP78 and CHOP signaling ER stress possible R–G Proteotoxic stress and apoptosis Usually secondary to ROS accumulation, covalent protein modification, and proteostasis disruption.
8 Proteasome and HSP90 chaperone function ↓ proteasome activity; ↓ HSP90 client stability Proteostasis toxicity possible R–G Oncoprotein destabilization May reduce AKT, HER2, survivin, and other short-lived or chaperone-dependent proteins.
9 PI3K AKT mTOR survival signaling ↓ PI3K; ↓ p-AKT; ↓ mTOR Context-dependent suppression R–G Reduced growth and stress adaptation May be partly downstream of oxidative stress and degradation of signaling proteins.
10 NF-κB and STAT3 signaling ↓ NF-κB; ↓ STAT3; ↓ survivin ↓ inflammatory signaling possible R–G Reduced survival and inflammatory transcription Contributes to apoptosis, reduced invasion, and sensitization to cytotoxic therapy.
11 Cell-cycle checkpoints ↑ p53 and p21; ↓ cyclin D1; ↑ arrest Growth arrest possible G Proliferation blockade Checkpoint and arrest phase vary among tumor models.
12 Autophagy and paraptosis ↑ autophagy; ↑ vacuolization; ↑ paraptosis Context-dependent stress response G Adaptive or non-apoptotic cell death Autophagy may be protective or cytotoxic; chloroquine can enhance GA activity in some models.
13 HIF-1α VEGF angiogenesis axis ↓ HIF-1α; ↓ VEGF; ↓ angiogenesis Potential impairment of physiological angiogenesis G Reduced tumor vascular support Preclinical effect; systemic antiangiogenic selectivity is not established.
14 Invasion and metastasis ↓ MMP-2; ↓ MMP-9; ↓ migration; ↓ EMT Limited direct evidence G Reduced invasive phenotype Likely integrates NF-κB, PI3K–AKT, HIF-1α, and cytoskeletal signaling effects.
15 Chemosensitization and drug resistance ↓ P-gp; ↓ survivin; ↑ chemotherapy sensitivity ↑ combination toxicity possible G Resistance reversal Synergy reported with doxorubicin, cisplatin, docetaxel, chloroquine, and other agents in preclinical models.
16 Radiosensitization ↑ radiation-induced ROS and cell death Potential ↑ normal-tissue radiation injury R–G Enhanced radiation response Preclinical and context-dependent; therapeutic selectivity remains uncertain.
17 Clinical Translation Constraint Exposure limited by solubility, metabolism, formulation and heterogeneity Kidney, liver and local irritation risks G Restricted therapeutic window Poor aqueous solubility, short systemic persistence, covalent off-target activity, CYP and transporter interactions, and weak controlled clinical evidence limit translation.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



older table (left here for references)
Rank Pathway / Target Axis Direction Primary Effect Notes / Cancer Relevance Ref
1 Thioredoxin / Thioredoxin reductase (Trx / TrxR) ↓ Trx / TrxR activity Redox buffering collapse Primary molecular target; covalent cysteine interaction drives loss of antioxidant capacity (ref)
2 ROS accumulation ↑ ROS Oxidative stress overload Immediate consequence of Trx/TrxR inhibition; upstream of mitochondrial damage (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Mitochondrial dysfunction GA reduces mitochondrial membrane potential prior to execution-phase death (ref)
4 Intrinsic apoptosis / pyroptosis (caspase-3, GSDME) ↑ programmed cell death Execution-phase killing Mitochondrial apoptosis and caspase-3/GSDME-dependent pyroptosis reported (ref)
5 NF-κB signaling ↓ NF-κB activation Reduced pro-survival transcription Redox-sensitive suppression of NF-κB nuclear activity and target genes (ref)
6 PI3K–AKT survival signaling ↓ AKT phosphorylation Survival pathway collapse Downstream of oxidative stress and chaperone disruption (ref)
7 HSP90 chaperone function ↓ client stabilization Oncoprotein destabilization GA disrupts HSP90–client interactions affecting AKT, HER2, etc. (ref)
8 ER stress / UPR ↑ ER stress signaling Proteotoxic stress Secondary ER stress response following redox and mitochondrial disruption (ref)
9 Cell cycle regulation ↑ cell-cycle arrest Proliferation blockade Checkpoint activation downstream of stress signaling (ref)
10 Autophagy (stress-induced) ↑ autophagy Adaptive or pro-death response Autophagy induction reported; role varies by context (ref)
11 Angiogenesis signaling (VEGF) ↓ VEGF expression Anti-angiogenic effect Suppression of pro-angiogenic transcription observed (ref)
12 Tumor growth in vivo ↓ tumor volume Integrated outcome Xenograft models show significant tumor growth inhibition (ref)


P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
5148- GamB,    Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics
- Review, Var, NA
AntiCan↑, angioG↓, ChemoSen↑, RadioS↑, VEGF↓, MMP2↓, MMP9↓, Telomerase↓, TrxR↓, ERK↓, HSP90↓, ROS↑, SIRT1↑, survivin↓, cFLIP↓, Casp3↑, Casp8↑, Casp9↑, BAD↓, BID↓, Bcl-2↓, BAX↑, STAT3↓, hTERT/TERT↓, NF-kB↓, Myc↓, Hif1a↓, FOXD3↑, BioAv↓, BioAv↑, P53↑, eff↓, OCR↓, MMP↓, PI3K↓, Akt↓, BBB↑, TumCG↓, TumMeta↓, BioAv↑,
5152- GamB,    Gambogic Acid as a Candidate for Cancer Therapy: A Review
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumCI↓, TumMeta↓, angioG↓, eff↑, NF-kB↓, P53↑, P21↑, MDM2↓, HSP90↓, Bcl-2↓, Cyt‑c↑, Casp↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑, Bax:Bcl2↑, ROS↑, SIRT1↓, TrxR1↓, Fas↓, FasL↑, FADD↑, APAF1↑, DNAdam↑, NF-kB↓, STAT3↓, MAPK↓, cFos↓, EGFR↓, Akt↓, mTOR↓, AMPK↑, TumCCA↑, ChemoSen↑, P-gp↓, survivin↓,
7059- GamB,    Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells
- in-vitro, CRC, HCT15
TumCP↓, Apoptosis↑, JNK↑, TumCCA↑, cycD1/CCND1↓, P53↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, MMP↓, Cyt‑c↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓,
7060- GamB,    New targets for the antitumor activity of gambogic acid in hematologic malignancies
- Review, Melanoma, RPMI-8226
AntiCan↑, TumCP↓, Apoptosis↑, SRC3↓, DIDO1/DIO-1↑, KCNH2/hERG↓, ROS↑, Bcl-2↓, P53↑, cMyc↓, VEGF↓, Casp3↑, cl‑PARP1↑, eff↓,
7063- GamB,    Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells
- vitro+vivo, Lung, H1299
TumCG↓, P53↑, MDM2↓, Apoptosis↑,
1959- GamB,    Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells
- in-vitro, Ovarian, NA - in-vivo, NA, NA
AntiCan↑, Pyro↑, tumCV?, CellMemb↓, cl‑Casp3↑, GSDME-N↑, ROS?, p‑P53↑, eff↓, MMP↓, Bcl-2↓, BAX↑, mtDam↑, Cyt‑c↑, TumCG↓, CD4+↑, CD8+↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

DIDO1/DIO-1↑, 1,   KCNH2/hERG↓, 1,   SRC3↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS?, 1,   ROS↑, 3,   TrxR↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 4,   mtDam↑, 1,   OCR↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 1,   SIRT1↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 4,   BAD↓, 1,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 5,   Bcl-xL↓, 1,   BID↓, 1,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp8↑, 2,   Casp9↑, 3,   cFLIP↓, 1,   Cyt‑c↑, 3,   FADD↑, 1,   Fas↓, 1,   FasL↑, 1,   GSDME-N↑, 1,   hTERT/TERT↓, 1,   JNK↑, 1,   MAPK↓, 1,   Mcl-1↓, 1,   MDM2↓, 2,   Myc↓, 1,   Pyro↑, 1,   survivin↓, 3,   Telomerase↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

FOXD3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV?, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP90↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 5,   p‑P53↑, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

cFos↓, 1,   ERK↓, 1,   mTOR↓, 1,   PI3K↓, 1,   STAT3↓, 2,   TumCG↓, 3,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP9↓, 1,   TumCI↓, 1,   TumCP↓, 2,   TumMeta↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   CellMemb↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   NF-kB↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 2,   eff↓, 3,   eff↑, 1,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   hTERT/TERT↓, 1,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 1,  
Total Targets: 87

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
6 Gambogic Acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:302  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page